ArticleEukaryotic cell2010
Galactoxylomannans from Cryptococcus neoformans varieties neoformans and grubii are structurally and antigenically variable.
Article in Eukaryotic cell, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Fungal extracellular vesicles mediate conserved cross-species communication and immunomodulation.mBio · 2026Article
- Conserved and rewired MAPK networks in human fungal pathogens.FEMS yeast research · 2026Review
- The structural language of fungal cell wall sugars in WHO priority fungi: the determinant of pathogenicity and the gateway to new therapies.Frontiers in immunology · 2026Review
- Comparative Analysis of Glucuronoxylomannogalactan and Glucuronoxylomannan Antibody Responses and Their Associations With Cryptococcal Disease Status in People With HIV.The Journal of infectious diseases · 2025Article
- Article
- Evolutionary uniqueeLife · 2025Article
- Antibody Isolation in C. neoformans.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Involvement of the capsular GalXM-induced IL-17 cytokine in the control of Cryptococcus neoformans infection.Scientific reports · 2018Article
- A role for LHC1 in higher order structure and complement binding of the Cryptococcus neoformans capsule.PLoS pathogens · 2014Article
- Pbx proteins in Cryptococcus neoformans cell wall remodeling and capsule assembly.Eukaryotic cell · 2014Article
- Unusual galactofuranose modification of a capsule polysaccharide in the pathogenic yeast Cryptococcus neoformans.The Journal of biological chemistry · 2013Article
- Disease-enhancing antibodies improve the efficacy of bacterial toxin-neutralizing antibodies.Cell host & microbe · 2013Article
- Article
- The Cryptococcus neoformans capsule: a sword and a shield.Clinical microbiology reviews · 2012Review
- Detection of urinary excreted fungal galactomannan-like antigens for diagnosis of invasive aspergillosis.PloS one · 2012Article
- Capsule independent uptake of the fungal pathogen Cryptococcus neoformans into brain microvascular endothelial cells.PloS one · 2012Article
- Chronological aging is associated with biophysical and chemical changes in the capsule of Cryptococcus neoformans.Infection and immunity · 2011Article
- Emerging themes in cryptococcal capsule synthesis.Current opinion in structural biology · 2011Review
- Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.Vaccine · 2011Article
- Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity.Molecular microbiology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Prior studies have established that the Cryptococcus neoformans capsular polysaccharide component galactoxylomannan (GalXM) manifests serotype-related structural differences that translate into antigenic differences. We analyzed GalXM from acapsular serotype A and D strains by carbohydrate analysis and static and dynamic light scattering to determine mass, effective diameter, polydispersity, and diffusion coefficients. Multiangle laser light scattering showed that GalXM from C. neoformans var. grubii strain cap59 (serotype A) had larger molecular mass (4.21 x 10(6) +/- 0.95 x 10(6) g/mol) and radius of gyration (207 +/- 27 nm) than GalXM from C. neoformans var. neoformans cap67 (serotype D). cap67 GalXM had corresponding values of 0.70 x 10(6) +/- 0.05 x 10(6) g/mol and 120 +/- 22 nm, respectively. The effective diameter for GalXM and polydispersity from the two strains varied depending on temperature and medium growth conditions, indicating that GalXM structure can vary within a strain, depending on its environment. Zeta potential determinations were negative for GalXM from both strains under all conditions, consistent with the recently reported presence of glucuronic acid. These results imply that C. neoformans GalXM, like glucuronoxylomannan, can manifest variety- and growth condition-related variations. Analysis of 16 C. neoformans and 7 Cryptococcus gattii strains with polyclonal antibody to a GalXM strain revealed antigenic similarities among the C. neoformans variety neoformans and grubii strains and no reactivity with C. gattii. As a result of the deleterious effects of GalXM on immune function, structural and antigenic variability between serotypes may translate into differences in immunomodulatory effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.